Press Releases

March 21, 2022

Summary Toggle Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

NEW YORK and LONDON, March 21, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
March 9, 2022

Summary Toggle Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

Broad-acting antihistamine has potential in number of disease areas with unmet clinical need NEW YORK and LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
March 8, 2022

Summary Toggle Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

NEW YORK and LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are
March 2, 2022

Summary Toggle Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5) NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company
February 28, 2022

Summary Toggle Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma

Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of trauma A follow-on program relevant to both military and civilian trauma is planned as the next steps toward a clinical study Project was funded by the DoD U.S.
February 11, 2022

Summary Toggle Akari Therapeutics to Present at BIO CEO & Investor Conference

NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today
January 26, 2022

Summary Toggle Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today
January 19, 2022

Summary Toggle FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and commercialization NEW YORK and LONDON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage
January 4, 2022

Summary Toggle Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today
December 30, 2021

Summary Toggle Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are

Akari TX

Press Releases

Press Releases

LONDON

NEW YORK

EXPANDED ACCESS POLICY

Skip links

Press Releases

Press Releases

Footer

LONDON

NEW YORK

EXPANDED ACCESS POLICY